sglt2 inhibitors and glp-1 receptor agonists Use of Among Patients with Type 1 Diabetes: A Nationwide Register-Based Cohort Study Metabolic Powerhouses: GLP-1 RAs and

Tens of thousands of new users were estimated to have started using GLP-1s every week in 2024, and it is estimated that at least half of the people in the U.S

Also in that trial, T2D and obesity were not inclusion criteria and the median BMI at baseline was 28 kg/m 2 in the liraglutide group and 29.8 kg/m 2 in the placebo group

Scientific Reference 2: Wilding et al., New England Journal of Medicine (2021) 2

Given that the glucose-lowering effect of metformin is so strong and is independent of incretin signalling, it might be difficult to detect the beneficial effect of metformin on the incretin axis in human studies

Food and Drug Administration : Finding and Learning About Side Effects (Adverse Reactions) Johns Hopkins Medicine: Allergies and the Immune System Stanford University: Why Animal Research

Semaglutide GLP-1 is capable of controlling the appetite to a degree and reducing the amount of food that patients will want to consume in order to help them lose weight long-term while combined with diet and exercise